AEAnnelot Clementine Mathilda van Esbroeck

Annelot Clementine Mathilda van Esbroeck

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Annelot Clementine Mathilda van Esbroeck has a total of 114 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Localization of Human UBE3A Isoform 3 is Highly Sensitive to Amino Acid Substitutions at p.Met21 Position

    by Annelot Clementine Mathilda van Esbroeck, Rob Franciscus Martinus Verhagen, Martina Biagioni, Matteo Fossati, Ben Distel, Ype Elgersma

    UBE3A encodes three isoforms of Ubiquitin E3 ligase A, which differ in their N-terminal sequence, abundance, and localization. Recently, three individuals diagnosed with Angelman Syndrome have been described who carry a variant that abrogates the start codon of the predominant nuclear isoform 1 (hUBE3A-Iso1 p.Met1Thr ) and concomitantly results in a missense variant in isoform 3 (hUBE3A-Iso1 p.Met21Thr ), which we previously reported to be nuclear enriched as well. Here, we studied the effect of the p.Met21Thr variant on hUBE3A-Iso3 localization. Recombinant expression of hUBE3A-Iso3 p.Met21Thr in U2-OS and mouse neurons revealed similar UBE3A labelling in the nucleus and cytosol, indicating hUBE3A-Iso3 localization is sensitive to amino acid changes at this position. This finding prompted us to revisit hUBE3A-Iso3 localization, since we previously introduced a p.Met21Ala/p.Met22Ala amino acid substitution in hUBE3A-Iso3 and its mouse orthologue mUBE3A-Iso2 to prevent translation of the shorter hUBE3A-Iso1 and mUBE3A-Iso3 nuclear isoforms. Introduction of silent mutations to disfavour translation of the short UBE3A isoforms enabled us to determine the localization hUBE3A-Iso3 and mUBE3A-Iso2 in the absence of amino acid changes at the p.Met21/p.Met22 position, respectively. Surprisingly, hUBE3A-Iso3 localization shifted from predominant nuclear localization for hUBE3A-Iso3 p.Met21Ala to a predominant cytosolic localization of the Kozak optimized hUBE3A-Iso3 KOZAK , while their mouse orthologues mUBE3A-Iso2 p.Met22Ala and mUBE3A-Iso2 KOZAK both localized predominantly to the cytosol. Taken together, these experiments indicate that the localization of human UBE3A-Iso3 is highly sensitive to amino acid substitutions at the p.Met21 position and that variants at this position not only abrogate the translation of hUBE3A-Iso1, but can also change the localization of hUBE3A-Iso3.

  • Discovery of a NAPE-PLD inhibitor that modulates emotional behavior in mice

    by Elliot D. Mock, Mohammed Mustafa, Ozge Gunduz-Cinar, Resat Cinar, Gavin N. Petrie, Vasudev Kantae, Xinyu Di, Daisuke Ogasawara, Zoltan V. Varga, Janos Paloczi, et al.

    N-acylethanolamines (NAEs), which include the endocannabinoid anandamide, represent an important family of signaling lipids in the brain. The lack of chemical probes that modulate NAE biosynthesis in living systems hamper the understanding of the biological role of these lipids. Using a high-throughput screen, chemical proteomics and targeted lipidomics, we report here the discovery and characterization of LEI-401 as a CNS-active N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD) inhibitor. LEI-401 reduced NAE levels in neuroblastoma cells and in the brain of freely moving mice, but not in NAPE-PLD KO cells and mice, respectively. LEI-401 activated the hypothalamus–pituitary–adrenal axis and impaired fear extinction, thereby emulating the effect of a cannabinoid CB1 receptor antagonist, which could be reversed by a fatty acid amide hydrolase inhibitor. Our findings highlight the distinctive role of NAPE-PLD in NAE biosynthesis in the brain and suggest the presence of an endogenous NAE tone controlling emotional behavior.


  • Activity-based protein profiling of the human failing ischemic heart reveals alterations in hydrolase activities involving the endocannabinoid system

    by Annelot C.M. van Esbroeck, Zoltan V. Varga, Xinyu Di, Eva J. van Rooden, Viktória E. Tóth, Zsófia Onódi, Mariusz Kuśmierczyk, Przemyslaw Leszek, Péter Ferdinandy, Thomas Hankemeier, et al.


  • Open Access

    Identification of α,β-Hydrolase Domain Containing Protein 6 as a Diacylglycerol Lipase in Neuro-2a Cells

    by Annelot C. M. van Esbroeck, Vasudev Kantae, Xinyu Di, Tom van der Wel, Hans Den Dulk, Anna F. Stevens, Simar Singh, Alexander T. Bakker, Bogdan I. Florea, Nephi Stella, et al.

    The endocannabinoid 2-arachidonoylglycerol (2-AG) is involved in neuronal differentiation. This study aimed to identify the biosynthetic enzymes responsible for 2-AG production during retinoic acid (RA)-induced neurite outgrowth of Neuro-2a cells. First, we confirmed that RA stimulation of Neuro-2a cells increases 2-AG production and neurite outgrowth. The diacylglycerol lipase (DAGL) inhibitor DH376 blocked 2-AG production and reduced neuronal differentiation. Surprisingly, CRISPR/Cas9-mediated knockdown of DAGLα and DAGLβ in Neuro-2a cells did not reduce 2-AG levels, suggesting another enzyme capable of producing 2-AG in this cell line. Chemical proteomics revealed DAGLβ and α,β-hydrolase domain containing protein (ABHD6) as the only targets of DH376 in Neuro-2a cells. Biochemical, genetic and lipidomic studies demonstrated that ABHD6 possesses DAGL activity in conjunction with its previously reported monoacylglycerol lipase activity. RA treatment of Neuro-2a cells increased by three-fold the amount of active ABHD6. Our study shows that ABHD6 exhibits significant DAG lipase activity in Neuro-2a cells in addition to its known MAG lipase activity and suggest it is involved in neuronal differentiation.


  • Two-step activity-based protein profiling of diacylglycerol lipase

    by Eva J. van Rooden, Roy Kreekel, Thomas Hansen, Antonius P. A. Janssen, Annelot C. M. van Esbroeck, Hans Den Dulk, Richard J. B. H. N. van Den Berg, Jeroen D. C. Codée, Mario van der Stelt

    Diacylglycerol lipases (DAGL) produce the endocannabinoid 2-arachidonoylglycerol, a key modulator of neurotransmitter release. Chemical tools that visualize endogenous DAGL activity are desired. Here, we report the design, synthesis and application of a triazole urea probe for DAGL equipped with a norbornene as a biorthogonal handle. The activity and selectivity of the probe was assessed with activity-based protein profiling. This probe was potent against endogenous DAGLα (IC50 = 5 nM) and it was successfully applied as a two-step activity-based probe for labeling of DAGLα using an inverse electron-demand Diels–Alder ligation in living cells.


  • Open Access

    Chemical Proteomic Analysis of Serine Hydrolase Activity in Niemann-Pick Type C Mouse Brain

    by Eva J. van Rooden, Annelot C. M. van Esbroeck, Marc P. Baggelaar, Hui Deng, Bogdan I. Florea, André R. A. Marques, Roelof Ottenhoff, Rolf G. Boot, Herman S. Overkleeft, Johannes M. F. G. Aerts, et al.

    The endocannabinoid system (ECS) is considered to be an endogenous protective system in various neurodegenerative diseases. Niemann-Pick type C (NPC) is a neurodegenerative disease in which the role of the ECS has not been studied yet. Most of the endocannabinoid enzymes are serine hydrolases, which can be studied using activity-based protein profiling (ABPP). Here, we report the serine hydrolase activity in brain proteomes of a NPC mouse model as measured by ABPP. Two ABPP methods are used: a gel-based method and a chemical proteomics method. The activities of the following endocannabinoid enzymes were quantified: diacylglycerol lipase (DAGL) α, α/β-hydrolase domain-containing protein 4, α/β-hydrolase domain-containing protein 6, α/β-hydrolase domain-containing protein 12, fatty acid amide hydrolase, and monoacylglycerol lipase. Using the gel-based method, two bands were observed for DAGL α. Only the upper band corresponding to this enzyme was significantly decreased in the NPC mouse model. Chemical proteomics showed that three lysosomal serine hydrolase activities (retinoid-inducible serine carboxypeptidase, cathepsin A, and palmitoyl-protein thioesterase 1) were increased in Niemann-Pick C1 protein knockout mouse brain compared to wild-type brain, whereas no difference in endocannabinoid hydrolase activity was observed. We conclude that these targets might be interesting therapeutic targets for future validation studies.


  • Design and Synthesis of Quenched Activity‐based Probes for Diacylglycerol Lipase and α,β‐Hydrolase Domain Containing Protein 6

    by E. J. van Rooden, M. Kohsiek, R. Kreekel, A. C. M. van Esbroeck, A. M. C. H. van Den Nieuwendijk, A. P. A. Janssen, R. J. B. H. N. van Den Berg, H. S. Overkleeft, M. van der Stelt

    Diacylglycerol lipases (DAGL) are responsible for the biosynthesis of the endocannabinoid 2‐arachidonoylglycerol. The fluorescent activity‐based probes DH379 and HT‐01 have been previously shown to label DAGLs and to cross‐react with the serine hydrolase ABHD6. Here, we report the synthesis and characterization of two new quenched activity‐based probes 1 and 2, the design of which was based on the structures of DH379 and HT‐01, respectively. Probe 1 contains a BODIPY‐FL and a 2,4‐dinitroaniline moiety as a fluorophore–quencher pair, whereas probe 2 employs a Cy5‐fluorophore and a cAB40‐quencher. The fluorescence of both probes was quenched with relative quantum yields of 0.34 and 0.0081, respectively. The probes showed target inhibition as characterized in activity‐based protein profiling assays using human cell‐ and mouse brain lysates, but were unfortunately not active in living cells, presumably due to limited cell permeability.


  • Mapping in vivo target interaction profiles of covalent inhibitors using chemical proteomics with label-free quantification

    by Eva J van Rooden, Bogdan I Florea, Hui Deng, Marc P Baggelaar, Annelot C M van Esbroeck, Juan Zhou, Herman S Overkleeft, Mario van der Stelt

    Activity-based protein profiling (ABPP) has emerged as a valuable chemical proteomics method to guide the therapeutic development of covalent drugs by assessing their on-target engagement and off-target activity. We recently used ABPP to determine the serine hydrolase interaction landscape of the experimental drug BIA 10-2474, thereby providing a potential explanation for the adverse side effects observed with this compound. ABPP allows mapping of protein interaction landscapes of inhibitors in cells, tissues and animal models. Whereas our previous protocol described quantification of proteasome activity using stable-isotope labeling, this protocol describes the procedures for identifying the in vivo selectivity profile of covalent inhibitors with label-free quantitative proteomics. The optimization of our protocol for label-free quantification methods results in high proteome coverage and allows the comparison of multiple biological samples. We demonstrate our protocol by assessing the protein interaction landscape of the diacylglycerol lipase inhibitor DH376 in mouse brain, liver, kidney and testes. The stages of the protocol include tissue lysis, probe incubation, target enrichment, sample preparation, liquid chromatography–mass spectrometry (LC–MS) measurement, data processing and analysis. This approach can be used to study target engagement in a native proteome and to identify potential off targets for the inhibitor under investigation. The entire protocol takes at least 4 d, depending on the number of samples.


  • Top Cited Papers

    Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474

    by Annelot C. M. van Esbroeck, Antonius P. A. Janssen, Armand B. Cognetta, Daisuke Ogasawara, Guy Shpak, Mark van der Kroeg, Vasudev Kantae, Marc P. Baggelaar, Femke M. S. de Vrij, Hui Deng, et al.

    A clue to a drug's neurotoxicity?: The drug BIA 10-2474 inhibits fatty acid amide hydrolase (FAAH), a lipase that degrades a specific endocannabinoid. On the basis of this activity, BIA 10-2474 was being developed as a potential treatment for anxiety and pain. In a phase 1 trial of the drug, one subject died, and four others suffered brain damage. As an initial step in investigating whether inhibition of off-target proteins by BIA 10-2474 might contribute to its clinical neurotoxicity, van Esbroeck et al. used activity-based proteomic assays to identify proteins targeted by the drug. Studying human cells and brain samples from subjects not associated with the trial, they found that BIA 10-2474 targeted several different lipases in addition to FAAH. It also substantially altered lipid metabolism in cultured neurons. Science , this issue p. 1084


  • Open Access

    Chemical Proteomics Maps Brain Region Specific Activity of Endocannabinoid Hydrolases

    by Marc P. Baggelaar, Annelot C. M. van Esbroeck, Eva J. van Rooden, Bogdan I. Florea, Herman S. Overkleeft, Giovanni Marsicano, Francis Chaouloff, Mario van der Stelt

    The biosynthetic and catabolic enzymes of the endocannabinoids tightly regulate endocannabinoid-mediated activation of the cannabinoid CB1 receptor. Monitoring the activities of these endocannabinoid hydrolases in different brain regions is, therefore, key to gaining insight into spatiotemporal control of CB1 receptor-mediated physiology. We have employed a comparative chemical proteomics approach to quantitatively map the activity profile of endocannabinoid hydrolases in various mouse brain regions at the same time. To this end, we used two different activity-based probes: fluorophosphonate-biotin (FP-biotin), which quantifies FAAH, ABHD6, and MAG-lipase activity, and MB108, which detects DAGL-α, ABHD4, ABHD6, and ABHD12. In total, 32 serine hydrolases were evaluated in the frontal cortex, hippocampus, striatum, and cerebellum. Comparison of endocannabinoid hydrolase activity in the four brain regions revealed that FAAH activity was highest in the hippocampus, and MAGL activity was most pronounced in the frontal cortex, whereas DAGL-α was most active in the cerebellum. Comparison of the activity profiles with a global proteomics data set revealed pronounced differences. This could indicate that post-translational modification of the endocannabinoid hydrolases is important to regulate their activity. Next, the effect of genetic deletion of the CB1 receptor was studied. No difference in the enzymatic activity was found in the cerebellum, striatum, frontal cortex, and hippocampus of CB1 receptor knockout animals compared to wild type mice. Our results are in line with previous reports and indicate that the CB1 receptor exerts no regulatory control over the basal production and degradation of endocannabinoids and that genetic deletion of the CB1 receptor does not induce compensatory mechanisms in endocannabinoid hydrolase activity.